US2009042791A1PendingUtilityA1

Integrin binding motif containing peptides and methods of treating skeletal diseases

60
Assignee: ACOLOGIX INCPriority: Aug 16, 2000Filed: Oct 26, 2007Published: Feb 12, 2009
Est. expiryAug 16, 2020(expired)· nominal 20-yr term from priority
A61P 3/12A61P 3/00A61K 38/1709C07K 14/705A61P 19/08C07K 14/78C07K 14/4705A61P 19/10A61P 19/00A61Q 11/00A61K 38/12C07K 14/4728C07K 14/47A61K 38/16A61K 38/06A61K 8/64A61K 38/08
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.

Claims

exact text as granted — not AI-modified
1 - 13 . (canceled) 
     
     
         14 . A method of reducing bone loss, comprising:
 administering to an individual a therapeutically effective amount of a formulation comprising:   a carrier; and   a peptide compound comprising at least 10 and not more than 50 naturally occurring amino acids the peptide compound comprising an integrin binding motif, a glycosaminoglycan binding motif, and a calcium binding motif.   
     
     
         15 . The method of  claim 14 , wherein the integrin binding motif is an RGD sequence. 
     
     
         16 . The method of  claim 14 , wherein the glycosaminoglycan motif has the sequence SGDG. 
     
     
         17 . The method of  claim 14 , wherein the calcium binding motif has the sequence DXDXSXFXGXXQ, wherein X is any amino acid. 
     
     
         18 . The method of  claim 17 , wherein the calcium binding motif has the sequence DNDISPFSGDGQ. 
     
     
         19 . The method of  claim 14 , wherein the carrier is a saline solution and the formulation is injectable. 
     
     
         20 . The method of  claim 14 , wherein the peptide comprises an amino acid sequence contiguous with a RGD sequence of naturally occurring matrix extracellular phosphoglycoprotein. 
     
     
         21 . The method of  claim 14 , wherein the peptide compound is a multimer. 
     
     
         22 . A patch for transdermal delivery of a peptide, a patch comprising:
 a carrier; and   a peptide compound comprising at least 10 and not more than 50 naturally occurring amino acids the peptide compound comprising an integrin binding motif, a glycosaminoglycan binding motif, and a calcium binding motif.   
     
     
         23 . A method of reducing renal phosphate excretion in an individual, comprising:
 administering to an individual a therapeutically effective amount of a formulation comprising:   a carrier; and   a peptide compound comprising at least 10 and not more than 50 naturally occurring amino acids the peptide compound comprising an integrin binding motif, a glycosaminoglycan binding motif, and a calcium binding motif.   
     
     
         24 . The method of  claim 23 , wherein the integrin binding motif is an RGD sequence. 
     
     
         25 . The method of  claim 23 , wherein the glycosaminoglycan motif has the sequence SGDG. 
     
     
         26 . ( The method of  claim 23 , wherein the calcium binding motif has the sequence DXDXSXFXGXXQ, wherein X is any amino acid. 
     
     
         27 . The method of  claim 26 , wherein the calcium binding motif has the sequence DNDISPFSGDGQ. 
     
     
         28 . The method of  claim 23 , wherein the carrier is a saline solution and the formulation is injectable.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.